David Keith Cundiff1. 1. Los Angeles County Hospital, USC Medical Center, Long Beach, California, USA. Dkcundiff3@verizon.net
Abstract
CONTEXT: In vitro studies and anecdotal clinical reports have suggested that clinically significant rebound hypercoagulability may occur after discontinuation of oral anticoagulants (OACs), such as vitamin K antagonists and ximelagatran, for venous thromboembolism (VTE). OBJECTIVE: Assess the extent to which rebound hypercoagulability-related VTE recurrences occur in the 2 months following discontinuation of OACs. DATA SOURCES: Published, randomized controlled trials (RCTs) of OAC treatment of VTE. STUDY SELECTION: RCTs of varying durations of OAC treatment of VTE that include VTE recurrence (or extension) data for more than 2 months after discontinuation of anticoagulants. DATA EXTRACTION: Rates of VTE recurrences (1) while taking OACs, (2) within 2 months of discontinuing OACs, and (3) from > 2 months until the end of the study were extracted along with major bleeding episodes while on OACs. The rate of VTE recurrences possibly attributable to rebound hypercoagulability was estimated by subtracting the VTE recurrence rate after the 2-month rebound period from the rate during the rebound period. DATA SYNTHESIS: In 20 trials (n = 5822), VTE recurrences were 2.62 times as frequent in the 2 months following discontinuation of OACs as subsequently (1.57% VTE recurrences per month falling to 0.56% per month, odds ratio = 2.62, 95% confidence interval: 2.19-3.14), corresponding to 2.02% of patients with rebound hypercoagulability-related VTE recurrences (1.57% per month - 0.56% per month x 2 months = 2.02%). In the 11 trials with evaluable data from the shorter- and longer-duration OAC arms, total adverse events (VTE recurrences plus major bleeding) over the entire durations of the trials were not significantly different. CONCLUSIONS: Rebound hypercoagulability accounts for about 2% of patients having recurrent VTE in the first 2 months after discontinuing OACs. RCTs evaluating the efficacy of OACs should include data for at least 2 months following OAC treatment. Increasing the duration of OAC treatment does not reduce the overall adverse events.
CONTEXT: In vitro studies and anecdotal clinical reports have suggested that clinically significant rebound hypercoagulability may occur after discontinuation of oral anticoagulants (OACs), such as vitamin K antagonists and ximelagatran, for venous thromboembolism (VTE). OBJECTIVE: Assess the extent to which rebound hypercoagulability-related VTE recurrences occur in the 2 months following discontinuation of OACs. DATA SOURCES: Published, randomized controlled trials (RCTs) of OAC treatment of VTE. STUDY SELECTION: RCTs of varying durations of OAC treatment of VTE that include VTE recurrence (or extension) data for more than 2 months after discontinuation of anticoagulants. DATA EXTRACTION: Rates of VTE recurrences (1) while taking OACs, (2) within 2 months of discontinuing OACs, and (3) from > 2 months until the end of the study were extracted along with major bleeding episodes while on OACs. The rate of VTE recurrences possibly attributable to rebound hypercoagulability was estimated by subtracting the VTE recurrence rate after the 2-month rebound period from the rate during the rebound period. DATA SYNTHESIS: In 20 trials (n = 5822), VTE recurrences were 2.62 times as frequent in the 2 months following discontinuation of OACs as subsequently (1.57% VTE recurrences per month falling to 0.56% per month, odds ratio = 2.62, 95% confidence interval: 2.19-3.14), corresponding to 2.02% of patients with rebound hypercoagulability-related VTE recurrences (1.57% per month - 0.56% per month x 2 months = 2.02%). In the 11 trials with evaluable data from the shorter- and longer-duration OAC arms, total adverse events (VTE recurrences plus major bleeding) over the entire durations of the trials were not significantly different. CONCLUSIONS: Rebound hypercoagulability accounts for about 2% of patients having recurrent VTE in the first 2 months after discontinuing OACs. RCTs evaluating the efficacy of OACs should include data for at least 2 months following OAC treatment. Increasing the duration of OAC treatment does not reduce the overall adverse events.
Authors: Russell D Hull; Graham F Pineo; Rollin F Brant; Andrew F Mah; Natasha Burke; Richard Dear; Turnly Wong; Roy Cook; Susan Solymoss; Man-Chiu Poon; Gary Raskob Journal: Am J Med Date: 2006-12 Impact factor: 4.965
Authors: L Pinede; J Ninet; P Duhaut; S Chabaud; S Demolombe-Rague; I Durieu; P Nony; C Sanson; J P Boissel Journal: Circulation Date: 2001-05-22 Impact factor: 29.690
Authors: M E Daskalopoulos; S S Daskalopoulou; E Tzortzis; P Sfiridis; A Nikolaou; D Dimitroulis; I Kakissis; C D Liapis Journal: Eur J Vasc Endovasc Surg Date: 2005-03-31 Impact factor: 7.069
Authors: M Cushman; R J Glynn; S Z Goldhaber; S Moll; K A Bauer; S Deitcher; S Shrivastava; P M Ridker Journal: J Thromb Haemost Date: 2006-07-26 Impact factor: 5.824
Authors: Harry R Buller; Ander T Cohen; Bruce Davidson; Hervé Decousus; Alex S Gallus; Michael Gent; Gerard Pillion; Franco Piovella; Martin H Prins; Gary E Raskob Journal: N Engl J Med Date: 2007-09-13 Impact factor: 91.245
Authors: Harry R Buller; Ander T Cohen; Bruce Davidson; Hervé Decousus; Alex S Gallus; Michael Gent; Gerard Pillion; Franco Piovella; Martin H Prins; Gary E Raskob Journal: N Engl J Med Date: 2007-09-13 Impact factor: 91.245
Authors: P Michael Ho; Eric D Peterson; Li Wang; David J Magid; Stephan D Fihn; Greg C Larsen; Robert A Jesse; John S Rumsfeld Journal: JAMA Date: 2008-02-06 Impact factor: 56.272
Authors: Joseph P Broderick; Jordan B Bonomo; Brett M Kissela; Jane C Khoury; Charles J Moomaw; Kathleen Alwell; Daniel Woo; Matthew L Flaherty; Pooja Khatri; Opeolu Adeoye; Simona Ferioli; Dawn O Kleindorfer Journal: Stroke Date: 2011-06-30 Impact factor: 7.914
Authors: Gary H Lyman; Marc Carrier; Cihan Ay; Marcello Di Nisio; Lisa K Hicks; Alok A Khorana; Andrew D Leavitt; Agnes Y Y Lee; Fergus Macbeth; Rebecca L Morgan; Simon Noble; Elizabeth A Sexton; David Stenehjem; Wojtek Wiercioch; Lara A Kahale; Pablo Alonso-Coello Journal: Blood Adv Date: 2021-02-23
Authors: Henrik Husted; Kristian Stahl Otte; Billy B Kristensen; Thue Ørsnes; Christian Wong; Henrik Kehlet Journal: Acta Orthop Date: 2010-10 Impact factor: 3.717
Authors: Thomas L Ortel; Ignacio Neumann; Walter Ageno; Rebecca Beyth; Nathan P Clark; Adam Cuker; Barbara A Hutten; Michael R Jaff; Veena Manja; Sam Schulman; Caitlin Thurston; Suresh Vedantham; Peter Verhamme; Daniel M Witt; Ivan D Florez; Ariel Izcovich; Robby Nieuwlaat; Stephanie Ross; Holger J Schünemann; Wojtek Wiercioch; Yuan Zhang; Yuqing Zhang Journal: Blood Adv Date: 2020-10-13